Department of Medicine, Clinical Sciences, Lund, Sweden.
Int Arch Allergy Immunol. 2010;152(1):71-4. doi: 10.1159/000260086. Epub 2009 Nov 24.
Two atopic patients suffering from severe allergy difficult to handle by conventional medication were given Xolair despite an IgE level <30 kU/l.
Increasing dosages were given and monitored by clinical evaluation and CD-sens to clinically relevant allergens. The patients' IgE antibody fractions were 11-14%.
Xolair dosages extrapolated from a recommended dose for IgE of 30-75 kU/l were adapted to the patients' IgE body pool but had very little effect. The double dose resulted in some clinical improvement and a decrease in CD-sens. However, not until the dose was doubled again did the patients become symptom free, although 1 patient needed some additional drugs but no oral steroids. CD-sens turned negative to 5 of the 7 tested allergens.
Xolair is most useful also in atopics with an IgE level <30 kU/l. The dose must be adjusted to the size of the IgE antibody fraction adding all non-cross-reacting, clinically relevant specificities.
两名患有严重过敏症的特应性患者，经常规药物治疗难以控制，尽管 IgE 水平<30 kU/L，仍给予茁乐（奥马珠单抗）。
通过临床评估和对临床相关过敏原的 CD-sens 监测，逐渐增加剂量。患者的 IgE 抗体分数为 11-14%。
根据 IgE 为 30-75 kU/L 的推荐剂量推断出的茁乐剂量，适应了患者的 IgE 体库，但效果甚微。双剂量导致了一些临床改善和 CD-sens 下降。然而，直到剂量再次加倍，患者才无任何症状，尽管 1 名患者仍需要一些额外的药物，但无需口服类固醇。CD-sens 对 7 种测试过敏原中的 5 种转为阴性。
即使 IgE 水平<30 kU/L，茁乐对特应性患者也最有用。必须根据 IgE 抗体分数的大小调整剂量，添加所有非交叉反应的、临床相关的特异性。
